- Home
- EDTK vs SNGX Comparison
EDTK vs SNGX Comparison
Compare EDTK & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | SNGX |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7M | 13.8M |
| IPO Year | 2020 | 1987 |
Fundamental Metrics
Financial Performance| Metric | EDTK | SNGX |
|---|---|---|
| Price | $1.00 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 2.7K | ★ 278.5K |
| Earning Date | 01-14-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $893,690.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $1.09 |
| 52 Week High | $1.20 | $6.23 |
Technical Indicators
Market Signals| Indicator | EDTK | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 56.76 |
| Support Level | $0.97 | $1.25 |
| Resistance Level | $1.06 | $1.60 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 42.28 | 85.37 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).